ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1041

Whole-Body Magnetic Resonance Imaging – A New Diagnostic Tool in the Assessment of Activity in Juvenile Dermatomyositis Patients?

Tania Monteiro de Castro1, Henrique Lederman1, Maria Teresa Terreri2, Wanda I. Caldana1, Edmar Zanoteli3 and Maria Odete Hilario1, 1Federal University of São Paulo, São Paulo, Brazil, 2Universidade Federal de São Paulo/UNIFESP, São Paulo, Brazil, 3University of São Paulo, São Paulo, Brazil

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: dermatomyositis, juvenile and whole-body, MRI

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Magnetic Resonance Imaging, Computed Tomography and X-ray

Session Type: Abstract Submissions (ACR)

Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune disorder, but remains the most commonly chronic inflammatory myopathy among children. A redefinition of the diagnostic criteria is currently underway and is likely to lead to non-invasive exams such as magnetic resonance (MR) imaging, in place of electromyography and muscle biopsy in the diagnosis of the disease.  Our goal was to demonstrate the benefit of whole-body MR imaging as a diagnostic tool in the detection of muscle inflammatory activity in JDM and to correlate these findings with clinical evaluation including muscle strength, laboratorial exams, nailfold capillaroscopy and muscle biopsy.

Methods: Thirty-three patients aged 6-19 years (median age, 12.1 years), 22 girls with a diagnose of JDM according to Bohan & Peter criteria were evaluated at any point during their illness course using clinical examination, muscle enzymes determination, muscle strength tests such as Childhood Myositis Assessment Scale (CMAS) and Manual Muscle Testing (MMT), nailfold capillaroscopy and short tau inversion recovery (STIR) whole-body MR imaging. JDM activity was evaluated by Disease Activity Score (DAS). An open muscle biopsy was performed in deltoids or biceps braquialis if muscle disease activity was detected on MR exam.

Results: Whole-body scanning gave a complete assessment of all muscles groups and disease activity was detected in STIR MR imaging in four (12.1%) patients confirmed by muscle biopsy. All four patients had elevation of at least one muscle enzyme and the nailfold capillaroscopy showed scleroderma (SD) pattern in these patients. CMAS, MMT and DAS means were 25.7, 32.3 and 9 respectively in patients with altered MR, and 48.1, 77 and 2.35 respectively in patients whose MR were normal. Twenty-nine patients had inactive disease (24 with medication and five without medication). Nailfold capillaroscopy was normal in 16 patients and with SD pattern in nine patients (not done in four patients). Muscle strength tests (CMAS and MMT) were normal in 16 out of 29 patients (MMT not done in four patients). 

Conclusion: Whole-body MR allows us to evaluate the extent and symmetry of muscle disease and inflammatory activity in a single exam by revealing muscles groups not seen with standard protocols. Nailfold capillaroscopy is an important additional exam to assess disease activity. Muscle strength tests are important to evaluate not only the disease in the acute phase, but the accumulated effect over the same time.


Disclosure:

T. Monteiro de Castro,
None;

H. Lederman,
None;

M. T. Terreri,
None;

W. I. Caldana,
None;

E. Zanoteli,
None;

M. O. Hilario,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/whole-body-magnetic-resonance-imaging-a-new-diagnostic-tool-in-the-assessment-of-activity-in-juvenile-dermatomyositis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology